 The U.S. Food and Drug Administration FDA has granted Fast Track Designation to PDS Biotechnologys NASDAQ: PDSB lead drug candidate PDS0101 in combination with KEYTRUDA pembrolizumab for the treatment of patients with recurrent or metastatic HPV16-positive head and neck cancer. 